Acquiring Company
ANI Pharmaceuticals
Acquired Company
Egetis Therapeutics AB (publ)
Princeton
SwedenBiotechnologyPharmaceuticalBiotechnologyTherapeuticsPharmaceuticalDescription
ANI Pharmaceuticals has announced a recommended public offer to acquire Egetis Therapeutics AB for SEK 11.25 per share, a 27% premium to the 60-day VWAP, valuing Egetis at about SEK 5.6 billion ($560M) and an enterprise value of about $434M after adjusting for expected proceeds from Egetis' sale of its Rare Pediatric Disease Priority Review Voucher. The offer is unanimously recommended by Egetis' Board and supported by shareholders controlling about 42 percent of the shares. The deal would add EMCITATE®, which ANI estimates could exceed $300 million in peak sales with protection into 2045.
Who to call at ANI Pharmaceuticals, and when
When ANI Pharmaceuticals changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day ANI Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at ANI Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at ANI Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ANI Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Egetis Therapeutics AB (publ)?
Egetis Therapeutics AB (publ) was acquired by ANI Pharmaceuticals, based in Princeton. The deal was reported on November 5, 2026. ANI Pharmaceuticals, Inc. is a global pharmaceutical company with a strategic focus on expanding its Rare Disease business. ANI Pharmaceuticals is publicly traded (ANIP) and operates in Biotechnology.
When did ANI Pharmaceuticals acquire Egetis Therapeutics AB (publ)?
ANI Pharmaceuticals's acquisition of Egetis Therapeutics AB (publ) was reported on November 5, 2026. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Egetis Therapeutics AB (publ) do?
Egetis Therapeutics is a commercial-stage pharmaceutical company developing therapies for rare diseases with significant unmet medical need. Its lead product, EMCITATE®, was approved by the European Commission in February 2025 and by the U.S. It is privately held, operating in Biotechnology, and is based in Sweden.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.